guest ::
| Home > Publications database > Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review. > print |
| Home > Publications database > Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review. > print |
| 001 | 293782 | ||
| 005 | 20250826104555.0 | ||
| 024 | 7 | _ | |a 10.1016/j.critrevonc.2024.104523 |2 doi |
| 024 | 7 | _ | |a pmid:39326645 |2 pmid |
| 024 | 7 | _ | |a 0737-9587 |2 ISSN |
| 024 | 7 | _ | |a 1040-8428 |2 ISSN |
| 024 | 7 | _ | |a 1879-0461 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-01940 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sprokkerieft, Julia |b 0 |
| 245 | _ | _ | |a Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2024 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1730895239_24895 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 204, December 2024, 104523 |
| 520 | _ | _ | |a Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Pediatric |2 Other |
| 650 | _ | 7 | |a axitinib |2 Other |
| 650 | _ | 7 | |a renal cell carcinoma |2 Other |
| 650 | _ | 7 | |a young adult |2 Other |
| 700 | 1 | _ | |a van der Beek, Justine N |b 1 |
| 700 | 1 | _ | |a Spreafico, Filippo |b 2 |
| 700 | 1 | _ | |a Selle, Barbara |0 P:(DE-He78)16933397bb16ab9603a3f27b4b314f81 |b 3 |
| 700 | 1 | _ | |a Chowdhury, Tanzina |b 4 |
| 700 | 1 | _ | |a Graf, Norbert |b 5 |
| 700 | 1 | _ | |a Verschuur, Arnauld C |b 6 |
| 700 | 1 | _ | |a Dandis, Rana |b 7 |
| 700 | 1 | _ | |a Bex, Axel |b 8 |
| 700 | 1 | _ | |a Geller, James I |b 9 |
| 700 | 1 | _ | |a Tytgat, Godelieve A M |b 10 |
| 700 | 1 | _ | |a van den Heuvel-Eibrink, Marry M |b 11 |
| 773 | _ | _ | |a 10.1016/j.critrevonc.2024.104523 |g p. 104523 - |0 PERI:(DE-600)2025731-4 |p 104523 |t Critical reviews in oncology, hematology |v 204 |y 2024 |x 0737-9587 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293782/files/1-s2.0-S104084282400266X-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293782/files/1-s2.0-S104084282400266X-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:293782 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)16933397bb16ab9603a3f27b4b314f81 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CRIT REV ONCOL HEMAT : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CRIT REV ONCOL HEMAT : 2022 |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|